NPPB and pulmonary arterial hypertension: Interestingly, however, a recent trial in which 40 PAH-CHD patients were switched from bosentan to macitentan, showed improved World Health Organization (WHO) functional class, NT-proBNP levels, and echocardiographic RV measures but noted no difference in events such as syncope and hospitalization for heart failure [66].